Anupam Rishi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/123980/publications.pdf

Version: 2024-02-01

lex
7
ıthors
.)

#	Article	IF	CITATIONS
1	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensityâ€modulated radiotherapy. Cancer, 2017, 123, 3691-3700.	4.1	99
2	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25ÂYears Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 159-169.	0.8	61
3	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus–Mediated Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1017-1027.	0.8	50
4	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 698-708.	0.8	48
5	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVIDâ€19 pandemic: The Princess Margaret experience and proposal. Cancer, 2020, 126, 3426-3437.	4.1	42
6	Morphologic and topographic radiologic features of human papillomavirusâ€related and –unrelated oropharyngeal carcinoma. Head and Neck, 2017, 39, 1524-1534.	2.0	37
7	Pretreatment CT and ¹⁸ Fâ€FDG PETâ€based radiomic model predicting pathological complete response and locoâ€regional control following neoadjuvant chemoradiation in oesophageal cancer. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 102-111.	1.8	22
8	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiotherapy and Oncology, 2021, 165, 94-102.	0.6	22
9	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 1208.	2.2	20
10	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 858-867.	0.8	19
11	High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecologic Oncology, 2020, 156, 349-356.	1.4	18
12	Partial Laryngeal IMRT for T2NO Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 941-949.	0.8	17
13	Outcome following radiotherapy for head and neck basal cell carcinoma with â€aggressive' features. Oral Oncology, 2017, 72, 157-164.	1.5	15
14	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. Oral Oncology, 2021, 114, 105167.	1.5	11
15	Pre―and Postâ€Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. Laryngoscope, 2021, 131, E1162-E1171.	2.0	9
16	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. Radiotherapy and Oncology, 2021, 157, 255-262.	0.6	4
17	Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. Oral Oncology, 2021, 120, 105419.	1.5	4
18	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. Clinical and Translational Radiation Oncology, 2020, 21, 69-76.	1.7	1

#	Article	IF	CITATIONS
19	Long-Term Clinical Outcomes and Sequelae of Therapy in Early-Stage Orbital Mucosa-Associated Lymphoid Tissue Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	O